On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl ®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease. This condition ...

An estimated 5.3 million Americans currently live with alzheimer's disease, and that number is expected to jump rapidly as the population ages. Some studies have suggested that taking ...

Five companies developing treatments for back pain, Alzheimer’s and Parkinson’s diseases, and innovative diagnosis technology to detect osteoarthritis and glaucoma have received fresh funding from the ...

“This work provides new opportunities for the development of the next generation of ChE inhibitors that specifically target AChE and BChE associated with AD pathology.” “This work provides new ...

Do individuals with Alzheimer’s disease feel pain? Alzheimer’s disease does not cause pain itself, but a person with the disease can experience pain from other sources. It is a great challenge to ...

A study published in the Journal of Medicinal Chemistry presents a new family of candidate compounds for the treatment of Alzheimer's disease and pain, which have shown promising effects in animal ...

Alzheimer’s disease has long resisted simple solutions, but a new line of research suggests an unexpected pairing could help keep the condition at bay: a marijuana-derived compound working alongside a ...